CTI specializes in the unique challenges associated with hepatic populations,

from mild to moderate liver disease to end stage acute and chronic liver disease.

Hepatology research includes a wide array of diseases affecting liver function that can stem from diverse etiologies including autoimmune conditions, malnutrition, cancer, and infectious disease complications. CTI’s therapeutic expertise specific to liver diseases is one of the driving forces behind our ability to successfully design and manage drug development programs in this area. We specialize in the unique challenges associated with hepatic populations, from mild to moderate liver disease to end stage acute and chronic liver disease. 

Our Medical Directors, including a former transplant surgeon, work closely with the rest of our organization so that project teams are familiar with hepatic diseases and associated complications. We attend industry meetings and are members of many hepatology related societies, including the American Association of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL), the International Liver Transplantation Society (ILTS), and Studies in Pediatric Liver Transplantation (SPLIT).

We offer our sponsors:

  • A medical affairs team that includes a former transplant surgeon
  • A deep therapeutic expertise, as well as relationships with academic and community medical centers
  • A history of working in complex and critically ill patient populations
  • Clinical operations and consulting teams comprised of therapeutic experts
  • An employee turnover rate less than half of the reported industry average, resulting in team continuity
  • Experience with first-in-human, first-in-class, and first-in-patient trials
  • Personal relationships with key investigators and site personnel
  • Executive management involvement on every project
  • CTI studies regularly exceed industry standards for enrollment, despite challenging patient populations
  • A proven track record of success with more than 100 drug and device approvals

Some of our adult and pediatric experience includes:

  • Advanced liver cancer
  • Acute-on-Chronic Liver Failure (ACLF)
  • Alcoholic cirrhosis
  • Autoimmune hepatitis
  • Crohn's Disease
  • Delayed graft function (DGF)
  • Early allograft dysfunction
  • Esophageal Varices
  • Fibrosis
  • Hepatic encephalopathy
  • Hepatitis B virus (HBV)
  • Hepatitis C virus (HCV)
  • Hepatitis D virus (HDV)
  • Hepatocellular carcinoma
  • Hyperammonemia
  • Ischemia reperfusion injury (IRI)
  • Lysosomal Acid Lipase Deficiency (LALD)
  • Liver transplant
  • Metabolic liver disease
  • Nonalcoholic steatohepatitis (NASH)
  • Organ rejection (acute cellular rejection [ACR] and antibody mediated rejection [AMR])
  • Phenylketonuria
  • Primary biliary cirrhosis
  • Short bowl syndrome
  • Thrombo-cytopenia
  • Ulcerative Colitis
  • Urea cycle Disorder